Industry Sponsored Research

ONGOING

No.	Research Title	Investigator	Status
1	AEGIS II – A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subject with Acute Coronary Syndrome	Dato’ Sri Dr. Haji Azhari Rosman	Enrollment
2	APPIRED III – Preventing Oxidative Stress Induced Ischemic Injury and Systemic Inflammation Complications During and After Invasive Cardiac Surgery with Alkaline Phosphatase	Dr. Pau Kiew Kong	Enrollment
3	ABILITY DIABETES – Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diebetes Mellitus Global.	Dato’ Dr. Amin Ariff Nuruddin	Enrollment
4	COMBINE-INTERVENE – COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events.	Dato’ Dr. Amin Ariff Nuruddin	Enrollment
5	LEADR: Lead Evaluation for Defibrillation and Reliability	Dr. Surinder Kaur Khelae	Enrollment
6	CTO Registry using the HYBRID CTO ALGORITHM at IJN. (Device : Crossboss & Stingray)	Datuk Dr. Shaiful Azmi Yahaya	Enrollment
7	FINEARTS – A multicentre, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure(NYHA II-IV) and EF ≥40%	Dr. Teoh Chee Kiang	Enrollment
8	DEDICATE REGISTRY – A Post Market Registry of Abluminum® Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetic Mellitus	Dato’ Sri Dr. Haji Azhari Rosman	Enrollment
9	GSR DEFINE: Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE study	Dato’ Dr. Amin Ariff Nuruddin	Enrollment
10	FIM-IBS – A Prospective, Non-randomized, Open lable, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System	Datuk Dr. Shaiful Azmi Yahaya	Enrollment
11	ZEUS-Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation	Dato’ Sri Dr. Haji Azhari Rosman	Enrollment
12	MID-Q Response	Datuk Dr. Azlan Hussin	Enrollment
13	NEOS-APAC-Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO	Mr. Paneer Selvam	Enrollment
14	RESTORE: A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging	Dr. Geetha A/P Kandavello @ Kandhavel	Enrollment
15	TOMORROW – A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children with Pulmonary Arterial Hypertension	Dr. Geetha A/P Kandavello @ Kandhavel	Enrollment
16	VFAHF STUDY – Ventricle from Atrium Heart Failure Clinical Study (VFAHF)	Datuk Dr. Azlan Hussin	Enrollment
17	SALTO – A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension	Dr. Geetha A/P Kandavello @ Kandhavel	Enrollment
18	SCORE REGISTRY: Sequent® SCB ‘’All Comers’’ Post Market Clinical Follow up (PMCF)	Dato’ Dr. Amin Ariff Nuruddin	Enrollment
19	STRIDE: Effects of semaglutide on functional capacity in patients withtype 2 diabetes and peripheral arterial disease	Datuk Dr. Shaiful Azmi Yahaya	Enrollment
20	PRIME-FFR: Prognostic impact of lesion-specific hemodynamic index and disease characteristics in patients with coronary artery disease assessed by fractional flow reserve	Dato’ Sri Dr. Haji Azhari Rosman	Enrollment

No.	Research Title	Investigator	Status
1	BIOLUX P-III REGISTRY: BIOTRONIK-A Prospective, International, Multi-Centre, Post-Market All-Comers Registry To Assess The Clinical Performance Of The Passeo-18 Lux Paclitaxel Releasing Balloon Catheter In Infraguinal Arteries -III	Datuk Dr. Shaiful Azmi Yahaya	Follow Up
2	Meres-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study Of Meres100 Sirolimus Eluting Bioresorbable Vascular Scaffold System In The Treatment Of De-Novo Native Coronary Artery Lesions	Dato’ Dr. Amin Ariff Nuruddin	Follow Up
3	ABSORB BVS: Comparative Study In Real World Use Of The ABSORB Bioresorbable Vascular Scaffold In De Novo Coronary Artery Disease Among Diabetes And Non-Diabetes Patient In Institut Jantung Negara, Malaysia: A Prospective Post-Marketing Single-Center Registry	Datuk Dr. Shaiful Azmi Yahaya	Follow Up
4	CONSEQUENT ALL COMERS: Clinical PMCF on Peripheral Arteries treated with SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population	Datuk Dr. Shaiful Azmi Yahaya	Follow Up
5	ISCHEMIA – International Study of Comparative Health Effectiveness With Medical and Invasive Approaches	Datuk Dr. Ahmad Khairuddin Mohamed Yusof	Follow Up
6	The EASTBOURNE Registry: The All-comers Sirolimus-coated balloon European registry.	Dato’ Dr. Amin Ariff Nuruddin	Follow Up
7	SCB DE-NOVO STUDY: Treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter	Dato’ Dr. Amin Ariff Nuruddin	Follow Up
8	BIOSOLVE-IV REGISTRY: Safety And Performance In De Novo Lesion Of Native Coronary Arteries With Magmaris – Registry Data	Dato’ Dr. Amin Ariff Nuruddin	Follow Up
9	MYHF: Malaysian National Heart Failure Registry	Dato’ Dr. Azmee Bin Mohd Ghazi	Follow Up
10	SELECT STUDY: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Dato’ Sri Dr. Haji Azhari Rosman	Follow Up
11	BGSAMIRP: Blood-based Genomic Signatures in Acute Myocardial Infarction Risk Prediction	Dato’ Dr. Amin Ariff Nuruddin	Follow Up
12	CAAN-AF: Cardiac Resynchronization therapy (CRT) And AV Node ablation in Atrial Fibrillation	Datuk Dr. Azlan Hussin	Follow Up
13	PROTECT-ICD Trial: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction	Dr. Geetha A/P Kandavello @ Kandhavel	Follow Up
14	CRYO AF GLOBAL REGISTRY	Dr. Surinder Kaur Khelae	Follow Up
15	A DUE: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy	Dr. Geetha A/P Kandavello @ Kandhavel	Follow Up
16	BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT)	Datuk Dr. Shaiful Azmi Yahaya	Follow Up
17	MICRA AV: Product Surveillance Registry (PSR)	Datuk Dr. Azlan Hussin	Follow Up

As at 29 Nov 2022

COMPLETED